Citicoline for acute ischemic stroke in mexican hospitals: A retrospective postmarketing analysis

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 32, Issue 5, 2010, Pages 325-330

  Leon Jimenez C ^a   Chiquete, E ^b,c   Cantu C ^d   Miramontes Saldana M J ^a   Andrade Ramos, M A ^c   Ruiz Sandoval, José Luis ^b  

^a Hospital Regional Dr Valentin Gomez Farias   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CITICOLINE; NEUROPROTECTIVE AGENT;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; CRANIECTOMY; DATA BASE; DECUBITUS; DRUG EXPOSURE; FEMALE; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; PNEUMONIA; POSTMARKETING SURVEILLANCE; RANKIN SCALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY TRACT INFECTION; ACUTE DISEASE; MIDDLE AGED; STROKE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CYTIDINE DIPHOSPHATE CHOLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; STROKE;

EID: 79952113397     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2010.32.5.1465004     Document Type: Article

References (33)

1. Gladstone, D.J., Black, S.E., Hakim, A.M. Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33(8): 2123-36.
2. Diener, H.C., Lees, K.R., Lyden, P. et al. NXY-059 for the treatment of acute stroke: Pooled analysis of the SAINT I and II trials. Stroke 2008, 39(6): 1751-8.
3. O'Collins, V.E., MacLeod, M.R., Donnan, G.A., Horky, L.L., Van Der Worp, B.H., Howells, D.W. 1,026 experimental treatments in acute stroke. Ann Neurol 2006, 59(3): 467-77.
4. Tazaki, Y., Sakai, F., Otomo, E. et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind controlled study. Stroke 1988, 19(2): 211-6.
5. Clark, W.M., Warach, S.J., Pettigrew, L.C., Gammans, R.E., Sabounjian, L.A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicholine Stroke Study Group. Neurology 1997, 49(3): 671-8.
6. Clark W.M., Williams B.J., Selzer K.A., Zweifler R.M., Sabounjian L.A., Gammans R.E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999, 30(12): 2592-7.
7. Warach, S., Pettigrew, L.C., Dashe, J.F. et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000, 48(5): 713-22.
8. Baskaya, M.K., Dogan, A., Rao, A.M., Dempsey, R.J. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 2000, 92: 448-52.
9. Clark, W.M., Wechsler, L.R., Sabounjian, L.A., Schwiderski, U.E. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001, 57(9): 1595-602.
10. Dávalos, A., Castillo, J., Alvarez-Sabín, J. et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke 2002, 33(12): 2850-7.
11. Secades, J.J., Lorenzo, J.L. Citicoline: Pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006, 28(Suppl. B): 1-56.
12. Secades, J.J., Alvarez-Sabín, J., Rubio, F. et al. Citicoline in intracerebral haemorrhage: A double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 2006, 21(5-6): 380-5.
13. Fioravanti, M., Buckley, A.E. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging 2006, 1(3): 247-51.
14. Cho, H.J., Kim, Y.J. Efficacy and safety of oral citicoline in acute ischemic stroke: Drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol 2009, 31(3): 171-6.
15. Mackay, J., Mensah, G.A. (Editors): The Atlas of Heart Disease and Stroke. World Health Organization. Myriad Editions Ltd., Brighton, 2004.
16. Hacke, W., Donnan, G., Fiesch, C. et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363(9411): 768-74.
17. Hacke, W., Kaste, M., Bluhmki, E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359(13): 1317-29.
18. Wahlgreen, N., Ahmed, N., Dávalos, A. et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008, 372(9646): 1303-9.
19. Durai Pandian, J., Padma, V., Vijaya, P., Sylaja, P.N., Murthy, J.M. Stroke and thrombolysis in developing countries. Int J Stroke 2007, 2: 17-26.
20. Lees, K.R., Asplund, K., Carolei, A. et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN international) in patients with acute stroke. A randomised controlled trial. GAIN International Investigators. Lancet 2000, 355(9219): 1949-54.
21. Muir, K.W., Lees, K.R., Ford, I., Davis, S. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial). A randomised controlled trial. Lancet 2004, 363(9407): 439-45.
22. Martínez, H.R., Rangel-Guerra, R.A., Marfil-Rivera, A., Muñiz, C.E., Sagástegui, A. Cost of stroke in Mexico. J Stroke Cerebrovasc Dis 1995, 4: 244-47.
23. Stroke trials registry. The Internet Stroke Center. Accessed October 12, 2008. (http://www.strokecenter.org/trials).
24. Ruiz-Sandoval, J.L., Murillo-Bonilla, L.M., Chiquete, E. et al. First Mexican multicenter register on ischemic stroke (the PREMIER Study): Demographics, risk factors and outcome. Stroke 2009, 40(4): S85.
25. Epstein, D., Mason, A., Manca, A. The hospital costs of care for stroke in nine European countries. Health Econ 2008, 17(S1): S21-31.
26. Banna, P., Marcello, M.F., Murabito, R. et al. Ultrastructural changes of the pulmonary parenchyma after experimentally induced endotoxic shock in dogs with and without drug protection. Respiration 1985, 47(3): 177-84.
27. Dulchavsky, S.A., Ksenzenko, S.M., Saba, A.A., Diebel, L.N. Triiodothyronine (T3) supplementation maintains surfactant biochemical integrity during sepsis. J Trauma 1995, 39(1): 53-7.
28. Yilmaz, Z., Ilcol, Y.O., Torun, S., Ulus, I.H. Intravenous administration of choline or CDP-choline improves platelet count and platelet closure times in endotoxin-treated dogs. Shock 2006, 25(1): 73-9.
29. Jambou, R., El-Assaad, F., Combes, V., Grau, G.E. Citicoline (CDP-choline): What role in the treatment of complications of infectious diseases. Int J Biochem Cell Biol 2009, 41(7): 1467-70.
30. Boismare, F.R., Leponcin, M., Lefrancois, J.P., Hacpille, L., Marchand, J.C. [Effect of cytidine diphosphocholine on hemodynamic, functional and biochemical consequences of cranio-cervical trauma in rats]. Thérapie 1977, 32: 345-54.
31. Hurtado, O., Moro, M.A., Cárdenas, A., et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: Effects on glutamate transport. Neurobiol Dis 2005, 18(2): 336-50.
32. Dziedzic, T., Slowik, A., Pera, J., Szczudlik, A. Beta-blockers reduce the risk of early death in ischemic stroke. J Neurol Sci 2007; 252(1): 53-56.
33. Sander, D., Winbeck, K., Klingelhöfer, J., Etgen, T., Conrad, B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 2001, 57(5): 833-8.